Safety Rates Drug Report: adverse events in 2016 Q3 - FDA prescription drugs adverse events in an open, searchable, online, public database

Drug Injury Quarter

Person who experienced the adverse event (patient)

Event ID	CASEID	CASEVERSION	I F COD	EVENT DT	MFR DT	INIT FDA DT	FDA DT	REPT COD	AUTH NUM	MFR NUM	MFR SNDR	LIT REF	AGE	AGE COD	AGE GRP	GNDR COD	E SUB	WT	WT COD	REPT DT	TO MFR	OCCP COD	REPORTER COUNTRY	OCCR COUNTRY
125791912	12579191	2	F	201309	20160805	20160721	20160805	EXP		TW-BAYER-2016-136787	BAYER		26.00	YR	A	F	Y	0.00000		20160805		CN	TW	TW

Drug(s) used by person

Event ID	CASEID	DRUG SEQ	ROLE COD	DRUGNAME	PROD AI	VAL VBM	ROUTE	DOSE VBM	CUM DOSE CHR	CUM DOSE UNIT	DECHAL	RECHAL	LOT NUM	EXP DT	NDA NUM	DOSE AMT	DOSE UNIT	DOSE FORM	DOSE FREQ
125791912	12579191	1	PS	NEXAVAR	SORAFENIB	1		800 MG, QD							21923	800	MG	FILM-COATED TABLET	QD
125791912	12579191	2	C	INTERFERON ALFA NOS	INTERFERON ALFA-2A OR INTERFERON ALFA-2B	1		UNK							0

Indications of drugs used

Event ID	CASEID	INDI DRUG SEQ	INDI PT
125791912	12579191	1	Metastatic renal cell carcinoma
125791912	12579191	2	Metastatic renal cell carcinoma

Outcome of event

Event ID	CASEID	OUTC COD
125791912	12579191	OT

Reactions reported

Event ID	CASEID	PT
125791912	12579191	Asthenia
125791912	12579191	Cachexia
125791912	12579191	Conjunctivitis
125791912	12579191	Hyponatraemia
125791912	12579191	Metastases to lymph nodes
125791912	12579191	Metastases to skin
125791912	12579191	Mucosal inflammation
125791912	12579191	Palmar-plantar erythrodysaesthesia syndrome
125791912	12579191	Renal cell carcinoma stage IV
125791912	12579191	Somnolence
125791912	12579191	Vaginal infection

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

no results found

Therapies reported

Event ID	CASEID	DSG DRUG SEQ	START DT	END DT	DUR	DUR COD
125791912	12579191	1	201308	201309	0
125791912	12579191	2	201307		0